Marker Therapeutics Inc MRKR

NAS: MRKR | ISIN: US57055L1070   30/04/2025
1,190 USD (-3,25%)
(-3,25%)   30/04/2025

9 december 2021 · Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors · Persbericht

18 november 2021 · Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting · Persbericht

10 november 2021 · Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results · Persbericht

7 september 2021 · Marker Therapeutics to Present at Three Upcoming September Investor Conferences · Persbericht

19 augustus 2021 · Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas · Persbericht

10 augustus 2021 · Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results · Persbericht

28 juli 2021 · Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility · Persbericht

6 juli 2021 · Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML · Persbericht

16 juni 2021 · Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference · Persbericht

12 mei 2021 · Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results · Persbericht

29 april 2021 · Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 · Persbericht

28 april 2021 · Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting · Persbericht

16 maart 2021 · Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock · Persbericht

15 maart 2021 · Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference · Persbericht

12 maart 2021 · Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock · Persbericht

11 maart 2021 · Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock · Persbericht

9 maart 2021 · Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results · Persbericht

3 maart 2021 · Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant · Persbericht

13 januari 2021 · Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates · Persbericht

5 januari 2021 · Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial · Persbericht

Mijn selecties